ORAMED PHARMACEUTICALS INC. (ORMP) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001176309 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 10, 2026 | — | $78.2M | $1.84 | Filing |
| Mar 31, 2026 | May 19, 2026 | — | $38.3M | $0.91 | Filing |
| Dec 31, 2025 | Mar 26, 2026 | — | $-54.0M | $0.25 | Filing |
| Sep 30, 2025 | Oct 24, 2025 | — | $48.4M | $1.13 | Filing |
| Jun 30, 2025 | Aug 14, 2025 | — | $13.3M | $0.31 | Filing |
| Mar 31, 2025 | May 15, 2025 | $2.0M | $-7.6M | $-0.19 | Filing |
| Dec 31, 2024 | Mar 27, 2025 | — | $8.9M | $-0.26 | Filing |
| Sep 30, 2024 | Nov 7, 2024 | — | $-19.6M | $-0.48 | Filing |
What would ORAMED PHARMACEUTICALS INC. have to report for its valuation to change?
At $4.18, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -38.7% a year, to $0.36. On that path the next quarter needs diluted EPS near $0.69, against $1.13 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -38.7% | -38.7% |
| EPS needed in final year | $0.36 | $0.36 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. ORMP goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.